Table 2 Significantly regulated transcripts of metabolic pathways in liver tissue within different ontogenetic stages (Ingenuity Pathway Analysis).
Ontogenetic stage | Regulated pathway | Direction of regulation | P value | No. of regulated genes | Genes involved in pathway |
|---|---|---|---|---|---|
94 dpc | Wnt signaling | up | 1.20*E-2 | 9 | ACVR1, CSNK1G3, FZD4, FZD6, MAP3K7, MMP7, TCF4, TCF7L2, WNT5A |
| Â | Mitotic roles of Polo-like kinase | down | 5.15*E-8 | 11 | CCNB1, CCNB2, CDC23, CDC25B, CDK1, FZR1, SP90AA1, KIF11, PLK1, PPP2R1B, PTTG1 |
| Â | G1/S checkpoint regulation | down | 2.76*E-5 | 8 | CCND2, CCND3, CCNE1, CDK4, E2F1, E2F4, RB1, TFDP1 |
| Â | G2/M DNA damage checkpoint regulation | down | 1.53*E-3 | 5 | CCNB1, CCNB2, CDC25B, CDK1, PLK1 |
1 dpn | - | - | - | - | - |
28 dpn | Complement system | up | 2.07*E-5 | 5 | C4B, C5, C6, C9, CD55 |
| Â | G1/S checkpoint regulation | down | 2.49*E-2 | 3 | CDKN1B, HDAC11, TGFB3 |
188 dpn | VEGF signaling | up | 2.80*E-4 | 12 | ACTA2, AKT3, BCL2, EIF2B1, KDR, MAPK1, MRAS, PIK3R3, PRKCB, RRAS2, VCL, VEGFC |
| Â | mTOR signaling | up | 6.29*E-3 | 13 | AKT3, EIF3B, EIF4B, MAPK1, MRAS, PIK3R3, PPP2CB, PRKAB2, PRKCB, RHOJ, RRAS2, TSC1, VEGFC |
| Â | Synthesis and degradation of ketone bodies | up | 1.18*E-3 | 4 | ACAA1, BDH1, HADHA, HADHB |
| Â | Bile acid synthesis | up | 3.33*E-3 | 7 | ACAA1, ADH5, ADHFE1, ALDH7A1, HADHA, HADHB, LIPA |
| Â | Fatty acid elongation in mitochondria | up | 4.81*E-3 | 4 | ACAA1, AUH, HADHA, HADHB |
| Â | Glucocorticoid receptor signaling | up | 3.99*E-2 | 17 | AKT3, BCL2, CCL2, GTF2A2, GTF2B, GTF2E2, HSP90AB1, HSPA1B, IL1RN, MAPK1, MRAS, NCOR1, PBX1, PIK3R3, RRAS2, TAF4, VCAM1 |
| Â | Val, Leu, Ile degradation | up | 8.32*E-3 | 8 | ACAA1, ACAD10, ALDH7A1, AUH, BCKDHB, HADHA, HADHB, HIBADH |
| Â | Biosynthesis of steroids | down | 7.65*E-3 | 5 | CYP24A1, CYP7B1, DHCR7, FDFT1, MVD |